×
戻る Agenda
Session 2: From Negative Controls to Novel Designs: Strengthening Clinical Development with Real-World Data and Evidence
Session Chair(s)
Representative Invited
Pacira Biosciences, United States
Session 2: From Negative Controls to Novel Designs: Strengthening Clinical Development with Real-World Data and Evidence
Speaker(s)
Representative Invited
Head of Oncology Statistical Innovation, Astrazeneca, United States
Negative Control for Generating Robust Real-World Evidence in Drug Development and Regulatory Decision-Making
Representative Invited
Data Scientist, Plinth Analytics, United States
Simulating Your Way to Success: From SAP to Study, Just Add Data
Representative Invited
Chief Executive Officer, Droice Labs, United States
Where Design Meets Delivery: Operationalizing Modern Trial Designs Using RWD/E for Regulatory Submissions